publication date: Jan. 17, 2014
20140117 - Jan. 17, 2014
ISSUE 3 – JAN. 17, 2014PDF

Officials: “Separations” in Normal Range
As Critics Claim Brain Drain in the Clinic

When surveyed by the Faculty Senate in October 2012, nearly a third of faculty members at MD Anderson Cancer Center who responded said they were likely to leave the institution within three years.

Of that number, 9.3 percent said they were likely to leave within one year.

photoAs Leadership Changes Continue, Fontaine, Leach Get New Posts
In another round of changes in the executive suite at MD Anderson Cancer Center, Dan Fontaine was appointed head the institutional advancement division, President Ronald DePinho announced in an email to the faculty and staff. 
photoNIH, NCI Get Higher Funding in 2014 Budget
Congress has passed a $1.012 trillion omnibus spending bill, easing the sequestration cuts set for fiscal 2014 and keeping the government open through September. President Barack Obama is expected to sign the bill by Saturday.
photoCDC: Lung Cancer Rates Drop Following Anti-Smoking Efforts
The rate of new lung cancer cases decreased among men and women from 2005 to 2009, largely due to tobacco control efforts, according to a report from the Centers for Disease Control and Prevention.
photoHoward Hughes Medical Institute Seeks up to 25 New Researchers
The Howard Hughes Medical Institute is seeking to appoint up to 25 new biomedical researchers through a national open competition. The initiative represents an investment of approximately $150 million in basic biomedical research over the next five years.
photoIn Brief

  • Baylor campus plans to build joint cancer center 
  • Beck named deputy director at Fox Chase Cancer Center 
  • Burtness named co-director of Yale Cancer Center Developmental Therapeutics Research Program
  • Dmitri Alden elected to French National Academy of Surgery
  • MD Anderson and Pfizer to launch immunotherapy collaboration
  • Regeneron Pharmaceuticals and Geisenger Health System to collaborate on genomics

Copyright (c) 2020 The Cancer Letter Inc.